FDA Approves First New Molecular Entity Under National Priority Voucher Program
The FDA approved the new molecular entity Foundayo (orforglipron), which represents the fifth approval granted under the Commissioner's National Priority Voucher (CNPV) pilot program.
This approval directly affects the manufacturer of Foundayo and regulatory professionals tracking the evolution of expedited review pathways and priority voucher programs.
This approval signals the continued activity and institutionalization of the CNPV pilot program. For regulatory professionals, it suggests that the voucher program remains a viable mechanism for accelerating the review of specific new molecular entities, though the source provides limited detail on the specific criteria that qualified this drug for the pilot.
Regulatory teams should monitor the progress of the CNPV pilot program to evaluate its viability for future drug development pipelines. Companies utilizing such vouchers must ensure all metabolic or other molecular entity documentation aligns with the program's specific evidentiary requirements.
The U.S. Food and Drug Administration today approved Foundayo (orforglipron) marking the fifth approval under the Commissioner's National Priority Voucher (CNPV) pilot program.
Open in openFDA / FDA.gov